The already beaten down pharma sector appears to be ready to take more hits over the next year or so, as major patents are set to expire, making room for generic competitors with cheaper prices to enter the playing field.
Here is a list of five major companies and the patents about to expire for them:
Pfizer, Inc. (PFE): Lipitor, expiring late 2011: $5.3 billion. Protonix, expiring 2011: $690 million. Viagra, 2012: $1.0 billion. Detrol / Detrol LA, 2012: $693 million.
GlaxoSmithKline, Inc. (GSK): Avandia expiring 2012: $367 million. Avodart, 2015: $523 million.
Merck and Co. (MRK): Singular,expiring 2012: $3.2 billion. Propecia, 2013: $447 million (worldwide).
Eli Lilly, Inc. (LLY): Zyprexa, expiring later 2011: $2.5 billion , Cymbalta, 2013: $2.77 billion . Roughly three-quarters of Lilly’s current revenue comes from eight drugs that will lose patent protection between now and 2017.
Pfizer was trading at $19.41m, gaining $0.05, or 0.23 percent, as of 12:08 PM EST. GlaxoSmithKline was trading at $38.49, up $0.09, or 0.23 percent. Merck was at $32.74, up $0.22, or 0.68 percent. Eli Lilly was at $34.83, up $0.06, or 0.17 percent. Bristol Myers Squibb was at $26.24, losing $0.02, or 0.10 percent.
No comments:
Post a Comment